Market Overview

Johnson & Johnson Seen As 'Safe Haven' By These Experts

Share:
Johnson & Johnson Seen As 'Safe Haven' By These Experts
  • Johnson & Johnson (NYSE: JNJ) shares have declined 13.28 percent year-to-date, from the high of $106.29 achieved on January 8.
  • Deutsche Bank’s Kristen Stewart has upgraded the company to Buy, maintaining a price target of $110.
  • Following meetings with the management, Stewart expressed confidence that the company was well positioned for growth across all its businesses, including pharma.

According to the Deutsche Bank report, “J&J has been active in portfolio mgmt, which we view positively. While it may have a few more small outbound transactions, inbound ones are now likely as its balance sheet capacity provides the opportunity to enhance growth.”

Analyst Kirsten Stewart also believes that the concerns regarding the growth outlook for the company’s pharmaceutical business have been overdone. Although some patent expirations and pipeline related risks could prove to be headwinds, Stewart expects the depth of Johnson & Johnson’s pipeline to “carry the company through.”

The company “expects to file more than 10 new molecular entities (NMEs) and more than 40 lines extensions by 2019,” Stewart reported, mentioning that two drugs that could turn into blockbusters were IMBRUVICA, which has already been approved, and daratumumab, which has been filed for approval.

“While JNJ’s MD&D and Consumer segments have seen modest growth as of late, we believe both are poised for improved growth given the portfolio rebalancing, new product launches, and resolution of division specific issues,” the report said.

In addition, Johnson & Johnson is one of the few companies with an AAA credit rating. Given that the company has $34 billion in marketable securities and cash and debt of only $19 billion, it is free to take on “to pursue M&A and/or licensing opportunities to improve its growth profile and do so in the best interest of shareholders,” Stewart added.

The EPS estimate for 2016 has been raised.

Latest Ratings for JNJ

DateFirmActionFromTo
Nov 2019Initiates Coverage OnOverweight
Oct 2019MaintainsOutperform
Oct 2019MaintainsOutperform

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Kristen StewartAnalyst Color Upgrades Analyst Ratings Best of Benzinga

 

Related Articles (JNJ)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
CCLSunTrust Robinson HumphreyDowngrades47.0
MGNXMorgan StanleyDowngrades6.0
TECKBMO CapitalDowngrades
RHLoop CapitalDowngrades190.0
NWEWells FargoUpgrades76.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Donald Drapkin Explains What Is Going On With Cliffs Natural Resources

Canaccord Analysts Recommend 'Aggressively Buying' AtriCure After Sell-Off